Evidence map›Paper›PMID 39753630›Full record

ArticleScientific reports2025

Chitosan nanoencapsulation of Turbinaria triquetra metabolites in the management of podocyturia in nephrotoxic rats.

Abdullah Abdel-Aal, Abdel-Aziz A F, Zakaria El-Khayat, Nadia Mohamed, Merit Rostom, Emad Tolba, Nihal Galal El-Din Shams El-Din, Walaa S A Mettwally, Abdelhamid Aly Hamdy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdullah Abdel-AalBiochemistry Division, Faculty of Science, Mansoura University, Mansoura, Egypt.
Abdel-Aziz A FBiochemistry Division, Faculty of Science, Mansoura University, Mansoura, Egypt.
Zakaria El-KhayatMedical Biochemistry Department, National Research Centre, Dokki, Giza, Egypt.
Nadia MohamedMedical Biochemistry Department, National Research Centre, Dokki, Giza, Egypt.
Merit RostomAcademy of Scientific Research and Technology, ASRT, Cairo, Egypt.
Emad TolbaPolymers and Pigments Department, National Research Centre, 33 El Bohouth St, Dokki, Cairo, 12311, Egypt.
Nihal Galal El-Din Shams El-DinNational Institute of Oceanography and Fisheries (NIOF), Cairo, Egypt.
Walaa S A MettwallyChemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute , National Research Centre, Dokki, Cairo, 12622, Egypt. walaa_sobieh@hotmail.com.
Abdelhamid Aly HamdyChemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute , National Research Centre, Dokki, Cairo, 12622, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin is a chemotherapeutic drug, which exhibits undesirable side effects. Chitosan nanoparticles are promising for drug delivery. The aim of this study was to determine the effect of the brown alga Turbinaria triquetra ethyl acetate fraction and polysaccharides, either loaded on chitosan nanoparticles or free, against podocyturia and cisplatin nephrotoxicity in rats. Sixty-six male rats were distributed into 11 equal groups: untreated control, chitosan (CSNPs), ethyl acetate fraction (EAE), polysaccharide (PS), EAE loaded on chitosan nanoparticles (EAE-CSNPs), PS loaded on chitosan nanoparticles (PS-CSNPs), Cisplatin or cis-diamminedichloroplatinum(II) (CDDP), CDDP + EAE, CDDP + PS, CDDP + EAE-CSNPs, and CDDP + PS-CSNPs. Serum urea, creatinine, creatinine clearance, renal malondialdehyde, nitric oxide, paraoxonase 1, renal nephrin, and podocin, and their renal mRNA gene expressions, as well as urinary nephrin and podocin were determined. The results indicated that the ethyl acetate fraction and polysaccharides, either free or loaded, efficiently attenuated podocyturia and cisplatin nephrotoxicity compared to the Cis group. However, the improvement was higher in the nephrotoxic groups treated with EAE-CSNPs and PS-CSNPs. The current study revealed that chitosan nanoencapsulation showed ameliorative effects against podocyturia and cisplatin nephrotoxicity in rats compared to free extracts, offering a new therapeutic strategy for attenuating podocyturia and CDDP-induced nephrotoxicity.

Indexed as

ChitosanCisplatinAnimalsKidneyKidney DiseasesMaleNanoparticlesPhaeophyceaePodocytesPolysaccharidesRatsChitosanCisplatinPolysaccharidesBrown algaChitosan nanoparticlesCisplatinNephrotoxicityPodocyturiaPolysaccharideTurbinaria Triquetra

Identifiers

PMID39753630
PMCPMC11698862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.